commander trial: iberdomide combinations to eliminate mrd after induction and autosct in myeloma
Published 8 hours ago • 11 plays • Length 3:21Download video MP4
Download video MP3
Similar videos
-
2:02
transplant trials in myeloma: emn02 and bmt ctn 0702
-
1:23
the importance of myeloma-specific frailty indices in trial design
-
2:31
stem cell collection in patients with multiple myeloma treated with anti-cd38 monoclonal antibodies
-
2:31
determining the optimal threshold to test mrd in multiple myeloma
-
2:21
mezigdomide: a novel celmod showing promise in the treatment of r/r myeloma
-
3:12
should we delay transplantation in patients with standard-risk multiple myeloma?
-
1:11:05
the utility of mrd testing for myeloma patient treatment and outcomes
-
6:23
how long will i live with multiple myeloma, and is there a cure? #myeloma
-
33:08
multiple myeloma
-
20:23
🎙️ podcast 69 | "charlando sobre el mieloma con maría antonieta mateos y jaime valero garcía
-
3:20
phase i trial of a bcma-cd3 bispecific antibody in r/r myeloma
-
1:08
real-world use of subcutaneous d-vtd in transplant-eligible patients with newly diagnosed myeloma
-
5:05
survival analysis of newly diagnosed transplant-eligible myeloma pts in the randomized forte trial
-
1:29
bispecific bcma-cd3 antibody teclistamab is efficacious and tolerable in r/r mm
-
8:36
alnuctamab, a bcma x cd3 t-cell engager, in pts with relapsed/refractory multiple myeloma
-
6:06
a breakthrough in myeloma testing
-
1:08
detecting clonal hematopoiesis in patients with waldenström's macroglobulinemia
-
3:31
safety and efficacy of multiantigen-targeted t cells for multiple myeloma
-
8:58
results of newly diagnosed transplant-eligible multiple myeloma patients enrolled in the forte trial
-
5:15
is mrd testing routinely recommended for myeloma patients?
-
3:50
engineered cells to target multiple myeloma
-
11:41
multiple myeloma - signs and symptoms, pathophysiology, treatment